{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:38:56Z","timestamp":1790199536403,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abnlynx a Sanofi Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40\u2009years on average. The goal of this study was to assess the incidence of aTTP in Germany.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A systematic review was performed to determine the published evidence on the aTTP epidemiology in Germany. To obtain additional evidence on the proportion of aTTP cases within the national Thrombotic Microangiopathy (TMA) population a hospital-level study was performed, using a retrospective data collection approach. Diagnosis of aTTP was confirmed if ADAMTS13 level were\u2009&lt;\u200910% and\/or the medical records explicitly mentioned aTTP diagnosis. The aggregated hospital data were then projected to the national level using logistic regression techniques.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The systematic literature search did not provide incidence estimates of aTTP in Germany. Eight centers (\u224827% of the top 30 TMA hospitals) delivered data according to a predefined data collection form. On average (year 2014\u20132016) a total number of 172 aTTP episodes per year was projected (95% confidence interval [95%CI]: 132\u2013212). The majority were newly diagnosed aTTP cases (<jats:italic>n<\/jats:italic>\u00a0=\u2009121; 95%CI: 105\u2013129), and 51 were recurrent aTTP cases (95%CI: 27\u201384). The average annual projected incidence (year 2014\u20132016) of aTTP episodes was 2.10 per million inhabitants in Germany (95%CI: 1.60\u20132.58).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The determined annual incidence of newly diagnosed aTTP cases and the overall annual incidence of aTTP episodes in Germany confirm the ultra-orphan character of aTTP. An external validation against international registries (France, UK and USA) shows that our findings are quite comparable with those international incidence rates.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1240-0","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T16:02:32Z","timestamp":1573833752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Menne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Feldkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm H.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Woitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Schwander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"issue":"1","key":"1240_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","volume":"112","author":"JE Sadler","year":"2008","unstructured":"Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11\u20138.","journal-title":"Blood."},{"issue":"4","key":"1240_CR2","doi-asserted-by":"publisher","first-page":"e0026","DOI":"10.5041\/RMMJ.10160","volume":"5","author":"G Sarig","year":"2014","unstructured":"Sarig G. ADAMTS-13 in the diagnosis and management of thrombotic microangiopathies. Rambam Maimonides Med J. 2014;5(4):e0026.","journal-title":"Rambam Maimonides Med J"},{"issue":"6","key":"1240_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/ndt\/gfl127","volume":"21","author":"D Patschan","year":"2006","unstructured":"Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006;21(6):1549\u201354.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1240_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/1744-9987.12191","volume":"19","author":"L Nichols","year":"2015","unstructured":"Nichols L, Berg A, Rollins-Raval MA, Raval JS. Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed? Ther Apher Dial. 2015;19(1):87\u201392.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"1240_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/trf.13586","volume":"56","author":"R Goel","year":"2016","unstructured":"Goel R, King KE, Takemoto CM, Ness PM, Tobian AA. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion. 2016;56(6):1451\u20138.","journal-title":"Transfusion."},{"issue":"8","key":"1240_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","volume":"97","author":"Y Benhamou","year":"2012","unstructured":"Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA reference center experience. Haematologica. 2012;97(8):1181\u20136.","journal-title":"Haematologica."},{"issue":"8","key":"1240_CR7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"25;115","author":"JA Kremer Hovinga","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;25;115(8):1500\u201311.","journal-title":"Blood"},{"issue":"12","key":"1240_CR8","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","volume":"122","author":"CC Deford","year":"2013","unstructured":"Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122(12):2023\u20139.","journal-title":"Blood."},{"issue":"suppl 1","key":"1240_CR9","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1111\/jth.12953","volume":"13","author":"SK Veseley","year":"2015","unstructured":"Veseley SK. Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost. 2015;13(suppl 1):S216\u2013S22.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1240_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","volume":"49","author":"QF Lewis","year":"2009","unstructured":"Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(1):118\u201324.","journal-title":"Transfusion."},{"issue":"8","key":"1240_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.24060","volume":"90","author":"B Han","year":"2015","unstructured":"Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015;90(8):709\u201314.","journal-title":"Am J Hematol"},{"issue":"6","key":"1240_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","volume":"49","author":"AS Kennedy","year":"2009","unstructured":"Kennedy AS, Lewis QF, Scott JG, Kremer Hovinga JA, Lammle B, Terrell DR, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(6):1092\u2013101.","journal-title":"Transfusion."},{"key":"1240_CR13","unstructured":"Veyradier A, editor PTT: \u00e9pid\u00e9miologie de la cohorte du CNR-MAT sur 16 ans. Compte rendu de la 8\u00e8 r\u00e9union du CNR-MAT; 2015 10\/16\/2015; Paris2015."},{"issue":"10","key":"1240_CR14","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","volume":"60","author":"JA Reese","year":"2013","unstructured":"Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60(10):1676\u201382.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"1240_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","volume":"1","author":"EE Page","year":"2017","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590\u2013600.","journal-title":"Blood Adv"},{"issue":"5","key":"1240_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","volume":"142","author":"M Scully","year":"2008","unstructured":"Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819\u201326.","journal-title":"Br J Haematol"},{"issue":"5","key":"1240_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.13654","volume":"171","author":"S Hassan","year":"2015","unstructured":"Hassan S, Westwood JP, Ellis D, Laing C, Mc GS, Benjamin S, et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP registry. Br J Haematol. 2015;171(5):830\u20135.","journal-title":"Br J Haematol"},{"issue":"7","key":"1240_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","volume":"3","author":"DR Terrell","year":"2005","unstructured":"Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432\u20136.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1240_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/01.ede.0000113273.14807.53","volume":"15","author":"DP Miller","year":"2004","unstructured":"Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, et al. Incidence of thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome. Epidemiology. 2004;15(2):208\u201315.","journal-title":"Epidemiology."},{"issue":"4","key":"1240_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139 w64.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1240_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer HJ, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312\u201322.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1240_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","volume":"106","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1):3\u201315.","journal-title":"Int J Hematol"},{"key":"1240_CR23","unstructured":"InEK GmbH. Fallpauschalen-Katalog, G-DRG-Version 2018 [Available from: https:\/\/www.g-drg.de\/content\/download\/7387\/55403\/version\/1\/file\/Fallpauschalen_Katalog_2018_171124.pdf."},{"key":"1240_CR24","unstructured":"Statistisches B. Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2014 2015 [Available from: https:\/\/www.destatis.de\/DE\/Publikationen\/Thematisch\/Gesundheit\/Krankenhaeuser\/TiefgegliederteDiagnosedaten.htm."},{"key":"1240_CR25","unstructured":"Statistisches B. Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2015. (Auszug aus Excel-Tabelle mit relevanten Daten) 2016 [Available from: https:\/\/www.destatis.de\/DE\/Publikationen\/Thematisch\/Gesundheit\/Krankenhaeuser\/TiefgegliederteDiagnosedaten.htm."},{"key":"1240_CR26","unstructured":"Statistisches B. Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2016. (Auszug aus Excel-Tabelle mit relevanten Daten) 2017 [Available from: https:\/\/www.destatis.de\/DE\/Publikationen\/Thematisch\/Gesundheit\/Krankenhaeuser\/TiefgegliederteDiagnosedaten.htm."},{"key":"1240_CR27","unstructured":"InEK GmbH. G-DRG-Browser 2014_2015 2016 [Available from: https:\/\/www.g-drg.de\/inek_site_de\/layout\/set\/einspaltig\/Media\/Files\/Datenbereitstellung\/G-DRG-Browser_2014_2015_Zip."},{"key":"1240_CR28","unstructured":"InEK GmbH. G-DRG-Browser 2015_2016 2017 [Available from: https:\/\/www.g-drg.de\/Datenbrowser_und_Begleitforschung\/Datenveroeffentlichung_gem._21_KHEntgG\/G-DRG-Browser_2015_2016."},{"key":"1240_CR29","unstructured":"InEK GmbH. G-DRG-Report-Browser 2017 2017 [Available from: http:\/\/www.g-drg.de\/Datenbrowser_und_Begleitforschung\/G-DRG-Report-Browser\/G-DRG-Report-Browser_2017."},{"key":"1240_CR30","unstructured":"Gemeinsamer B. Qualit\u00e4tsberichte der Krankenh\u00e4user in maschinenverwertbarer Form 2013\u20132015 2018 [updated 25.07.2018. Available from: https:\/\/www.g-ba.de\/institution\/themenschwerpunkte\/qualitaetssicherung\/qualitaetsdaten\/qualitaetsbericht\/xml-daten\/."},{"issue":"5","key":"1240_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/trf.14060","volume":"57","author":"T Falter","year":"2017","unstructured":"Falter T, Schmitt V, Herold S, Weyer V, von Auer C, Wagner S, et al. Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura. Transfusion. 2017;57(5):1152\u201362.","journal-title":"Transfusion."},{"issue":"2","key":"1240_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5482\/HAMO-12-11-0019","volume":"33","author":"T Falter","year":"2013","unstructured":"Falter T, Alber KJ, Scharrer I. Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes. Hamostaseologie. 2013;33(2):113\u201320.","journal-title":"Hamostaseologie."},{"key":"1240_CR33","unstructured":"Statistisches B. Zensus 2011 - Bev\u00f6lkerung am 9. Mai 2011 - Anteil Bev\u00f6lkerung unter 18 Jahren 2011 [Available from: https:\/\/www.destatis.de\/DE\/PresseService\/Presse\/Pressekonferenzen\/2013\/Zensus2011\/bevoelkerung_zensus2011.pdf;jsessionid=6EFE8209B0561B11F7D6E5D2DA1AD597.InternetLive1?__blob=publicationFile."},{"key":"1240_CR34","unstructured":"Statistisches B. Bev\u00f6lkerungsstand - Bev\u00f6lkerung nach Altersgruppen, Familienstand und Religionszugeh\u00f6rigkeit 2018 [Available from: https:\/\/www.destatis.de\/DE\/ZahlenFakten\/GesellschaftStaat\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/AltersgruppenFamilienstandZensus.html."},{"issue":"4","key":"1240_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1046\/j.1365-2141.2003.04049.x","volume":"120","author":"SL Allford","year":"2003","unstructured":"Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556\u201373.","journal-title":"Br J Haematol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1240-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:14:17Z","timestamp":1605312857000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1240-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1240-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Lead ethic committee approval by MHH (Medizinische Hochschule Hannover) \u2013 reference # 7773_BO_K_2018 (dated 14.02.2018) \u2013 each individual hospital requested ethic approval at the responsible local committees \u2013 on the basis of the lead ethic committee approval.Retrospective data collection approach based on anonymized data (no informed consent was necessary).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WM: Prof. Miesbach reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, personal fees from Shir, outside the submitted work.JM: Prof. Menne reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, personal fees from Sanofi Genzyme, personal fees from Alexion, outside the submitted work.MB: Dr. Bommer reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, personal fees from Sanofi, personal fees from Alexion, outside the submitted work.US: Dr. Sch\u00f6nermarck reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, personal fees from Alexion, outside the submitted work.TF: Prof. Feldkamp reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, personal fees from Akari, personal fees from Alexion, outside the submitted work.MN: Dr. Nitschke reports personal fees from Alexion, outside the submitted work.TW: Prof. Westhoff has nothing to disclose.FS: Dr. Seibert has nothing to disclose.RW: Prof. Woitas has nothing to disclose.RS: Dr. Sousa reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, outside the submitted work.MW: Mr. Wolf reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, outside the submitted work.SW: Dr. Walzer reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, outside the submitted work.BS: Mr. Schwander reports personal fees from Ablynx a Sanofi Company, during the conduct of the study; personal fees from Ablynx a Sanofi Company, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}